Navigation Links
Fatty spheres loaded with siRNA shrink ovarian cancer tumors in preclinical trial

A molecular "off" switch packaged in a tiny sphere penetrates deeply into ovarian cancer tumor cells, stifling a troublesome protein and drastically reducing the size of tumors, researchers at The University of Texas M. D. Anderson Cancer Center report in the Aug. 15 edition of Clinical Cancer Research.

The mouse model experiment, featured on the cover of the journal, demonstrates a potent delivery system for short interfering RNA (siRNA) to attack cancer, says senior author Anil Sood, M.D., associate professor in the Departments of Gynecologic Oncology and Cancer Biology at M. D. Anderson.

"Short interfering RNA is a great technology we can use to silence genes, shutting down production of harmful proteins," Sood says. "It works well in the lab, but the question has been how to get it into tumors." Short pieces of RNA don't make it to a tumor without being injected directly, and injection methods used in the lab are not practical for clinical use.

The research team took siRNA that targets a protein that helps ovarian cancer cells survive and spread and rolled it into a liposome -- a lipid ball so small that its dimensions are measured in nanometers (billionths of a meter).

Getting the siRNA inside tumor cells is important, Sood said, because the targeted protein, focal adhesion kinase (FAK), is inside the cell, rather than on the cell surface where most proteins targeted by cancer drugs are found. "Targets like FAK, which are difficult to target with a drug, can be attacked with this liposomal siRNA approach, which penetrates deeply into the tumor," Sood said.

Mice infected with three human ovarian cancer cell lines derived from women with advanced cancer were treated for 3-5 weeks. They received liposomes that contained either the FAK siRNA, a control siRNA, or were empty. Some mice received siRNA liposomes plus the chemotherapy docetaxel.

Mice receiving the FAK-silencing liposome had reductions in mean
'"/>

Source:University of Texas M. D. Anderson Cancer Center


Page: 1 2 3

Related biology news :

1. Fatty fish protects against cancer
2. Nanospheres that block pain of sensitive teeth
3. Engineer ramps up protein production, develops versatile viral spheres
4. Penn researchers show how nanocylinders deliver medicine better than nanospheres
5. Biodegradable microspheres deliver time release vaccines, stimulate different immune response
6. MWG Biotech expands siMAX?siRNA portfolio with new scales, lengths and design tools
7. Mice brains shrink during winter, impairing some learning and memory
8. Investigating brain shrinkage in alcoholics
9. Ultrasounds show mothers drinking shrinks fetal brain
10. Bird brains shrink from exposure to contaminants
11. Overfishing large sharks impacts entire marine ecosystem, shrinks shellfish supply
Post Your Comments:
(Date:8/28/2014)... MARC (Maximizing Access to Research Careers) Program has announced ... Human Genetics from October 18 22, 2014 in ... promote the entry of students, post doctorates and scientists ... science community and to encourage the participation of young ... This year MARC conferred 16 awards totaling $29,600., The ...
(Date:8/28/2014)... identified the developmental on-off switch for Streptomyces , ... two-thirds of the world,s naturally derived antibiotic medicines. ... it is possible to manipulate this switch to make ... appearing August 28 in Cell , found that ... and a larger protein called BldD ultimately controls whether ...
(Date:8/28/2014)... measuring and imaging how quickly blood flows in the ... drug abuse affects the brain, which may aid in ... better treatment options for recovering drug addicts. The new ... Brook University in New York, USA and the U.S. ... Optical Society,s (OSA) open-access journal Biomedical Optics ...
Breaking Biology News(10 mins):Small molecule acts as on-off switch for nature's antibiotic factory 2Small molecule acts as on-off switch for nature's antibiotic factory 3This is your brain's blood vessels on drugs 2This is your brain's blood vessels on drugs 3
... in Temple University,s College of Science and Technology has ... leptin receptor antagonist peptide, developed by researchers Laszlo Otvos ... triple negative breast cancer treatment, especially in the obese ... in the European Journal of Cancer . ...
... developed a novel method for eavesdropping on terahertz ... doctoral student at Rensselaer Polytechnic Institute has demonstrated ... boost the distance from which researchers can use ... chemicals, and other dangerous materials. Clough, ...
... the answer to how and why primates differ from other ... the repetitive stretches of the genome that were once considered ... of Iowa Carver College of Medicine finds that when a ... element, is inserted into existing genes, they can alter the ...
Cached Biology News:New peptide could be effective treatment for triple negative breast cancer 2Student innovation at Rensselaer holds key to safer remote detection of dangerous materials 2Student innovation at Rensselaer holds key to safer remote detection of dangerous materials 3U. Iowa team investigates function of 'junk DNA' in human genes 2U. Iowa team investigates function of 'junk DNA' in human genes 3
(Date:8/29/2014)... Albany, New York (PRWEB) August 29, 2014 ... be valued at $5.6 billion in 2019. It ... 18.1% from 2013 to 2019, and was valued ... research report published by Transparency Market Research. , ... please visit: http://www.transparencymarketresearch.com/companion-diagnostics-market.html . , The research ...
(Date:8/29/2014)... PA (PRWEB) August 29, 2014 Pittcon ... Hub MacDonald, and colleague Koichiro Matsuda, Horiba Scientific, have ... on September 5, 2014. JASIS , Asia’s largest ... 3-5, 2014, in Makuhari Messe, Japan. , The ... Tools for Bioanalysis from Single Molecules to Single Cells” ...
(Date:8/29/2014)... Local veterinarian, Dr. Keith Clement, and his ... to participate in an investigational study of donor stem ... of this study is to determine if a single ... arthritically affected joints can help reduce pain and inflammation ... current investigational study must be older than nine months, ...
(Date:8/29/2014)... 29, 2014 Due to a misstatement posted ... the Adult Stem Cell Technology Center, LLC ( ASCTC ) ... cell therapy research that might benefit ALS patients. Because ... new stem cell technologies and therapeutic applications, FRC listed ASCTC ... Challenge donors who wish not to support research that ...
Breaking Biology Technology:Companion Diagnostics Market to Hit $5.6 Billion in 2019: Transparency Market Research 2Companion Diagnostics Market to Hit $5.6 Billion in 2019: Transparency Market Research 3Fifth Annual U.S. Symposium at JASIS Organized by Pittcon’s Program Chairman Hub MacDonald 2Burnt Hills Veterinary Hospital Seeks Candidates for an Investigational Study of Stem Cells for Dogs with Arthritis 2The Adult Stem Cell Technology Center, LLC Declines ALS Ice Bucket Challenge Donors Wishing to Support Ethical Research for New Stem Cell Therapies 2The Adult Stem Cell Technology Center, LLC Declines ALS Ice Bucket Challenge Donors Wishing to Support Ethical Research for New Stem Cell Therapies 3
... SAN FRANCISCO, Jan. 10, 2011 Enobia Pharma Inc., ... II study of ENB-0040, a bone targeted enzyme replacement ... serious, rare metabolic bone disorder. The results were presented ... of Enobia, at the 29th Annual J.P. Morgan Healthcare ...
... (Nasdaq: PRXL ) will release Second Quarter Fiscal ... the close of the stock market.  The announcement will be ... the PR Newswire website at www.prnewswire.com . ... 10:00 a.m. EST on Tuesday, February 1, 2011 to discuss ...
... DuPont (NYSE: DD ) has entered ... a global enzyme and specialty food ingredients company, for ... of Danisco net debt.  Upon closing, this transaction would ... with science-intensive innovations that address global challenges in food ...
Cached Biology Technology:Enobia Announces Successful Completion of Phase II Juvenile Study of ENB-0040, a Bone Targeted Enzyme Replacement Therapy 2Enobia Announces Successful Completion of Phase II Juvenile Study of ENB-0040, a Bone Targeted Enzyme Replacement Therapy 3PAREXEL Announces Date of Second Quarter Fiscal Year 2011 Earnings Release and Conference Call 2DuPont to Acquire Danisco for $6.3 Billion 2DuPont to Acquire Danisco for $6.3 Billion 3DuPont to Acquire Danisco for $6.3 Billion 4
... conserved form of cell suicide, which follows ... component of this process is a cascade ... enzymes participate in a series of reactions ... signals and result in the cleavage of ...
... System provides optimized reagents and protocols for ... genes by insertion of group II introns. ... group II introns and utilizes a simple ... II intron for specific insertion into the ...
Mouse monoclonal antibody raised against a full length recombinant PPIL2. NCBI Entrez Gene ID = PPIL2...
Mouse monoclonal antibody raised against a partial recombinant QARS. NCBI Entrez Gene ID = QARS...
Biology Products: